The Technical AnalystExchange: ASX Industry: Pharmaceuticals, Biotechnology & Life Sciences
Proteomics International Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.41% $1.050
America/New_York / 2 mai 2024 @ 23:30
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 137.44 mill |
| EPS: | -0.0500 |
| P/E: | -21.00 |
| Earnings Date: | Jul 21, 2024 |
| SharesOutstanding: | 130.89 mill |
| Avg Daily Volume: | 0.280 mill |
| RATING 2024-05-02 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | n/a | |||||
| Ebit | n/a | |||||
| Asset | n/a | n/a | n/a | n/a | ||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -21.00 | sector: PE 1.258 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.55x |
| Company: PE -21.00 | industry: PE 38.27 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0278 (-102.65%) $-1.078 |
| Date: 2024-05-02 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.995 - 1.145 ( +/- 7.01%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.050 (-1.41% ) |
| Volume | 0.106 mill |
| Avg. Vol. | 0.280 mill |
| % of Avg. Vol | 37.88 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PIQ.AX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PIQ.AX
Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute and the Janssen Research & Development for the research of diabetic kidney disease treatment; and partnership with QIMR Berghofer Medical Research Institute for the detection of oesophageal adenocarcinoma. The company was founded in 2001 and is based in Perth, Australia.